% | $
Quotes you view appear here for quick access.

AstraZeneca PLC Message Board

  • kmaggon kmaggon Oct 28, 2010 12:39 AM Flag

    R&D setback

    AZN had a poor 2010 compared to its rivals in r&D efficiency. AZN had 2 NDA/BLA rejections by the FDA and 2 Phase III trial failures in cancer this year.

    A live updated review of new drug approvals, rejections and market withdrawals by the FDA and EMA in the year 2010 is provided. Safety issues derailed the approval of several new drugs, withdrawal of Meridia (Abbott) and Avandia (in Europe, restricted in the US). Pfizer had 3 new drugs approved by the FDA. Lilly R&D had a poor year with 3 Phase III failures and a BLA rejection. Roche, Novartis and Astra Zeneca each had 2 BLA/NDA rejected by the FDA and its advisory panel.

    New Drug Approvals FDA/EMA 2010

70.07+0.30(+0.43%)Mar 27 4:06 PMEDT